ETrade Capital Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

ETrade Capital Management’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	$1.6M	Sell	3,106 -79	-2%	-$40K	0.03%	259
2020 Q2	$1.44M	Buy	3,185 +129	+4%	+$56.9K	0.03%	262
2020 Q1	$1.07M	Sell	3,056 -68	-2%	-$25K	0.03%	276
2019 Q4	$1.16M	Sell	3,124 -34	-1%	-$12K	0.03%	323
2019 Q3	$1.05M	Sell	3,158 -37	-1%	-$12.1K	0.03%	334
2019 Q2	$999K	Buy	3,195 +101	+3%	+$30.2K	0.03%	346
2019 Q1	$946K	Buy	+3,094	New	+$835K	0.03%	343
2013 Q4	–	Sell	-18	Closed	-$2K	–	843
2013 Q3	$2K	Buy	+18	New	+$2.12K	﹤0.01%	835

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

ACM

Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

ETrade Capital Management's BIO Position: Q3 2020 in Review

ETrade Capital Management reduced its Bio-Rad Laboratories Class A (BIO) stake by 2.5% in Q3 2020, selling an estimated $40K and leaving 3,106 shares worth $1.6M. The position accounts for 0.03% of the portfolio, ranked #259.

ETrade Capital Management first reported a position in BIO in Q3 2013 and has held it in 8 quarters since. 479 funds tracked by Wall St. Rank hold BIO as of Q3 2020.

ETrade Capital Management held 3,106 shares of Bio-Rad Laboratories Class A worth $1.6M as of Q3 2020.
ETrade Capital Management sold 79 Bio-Rad Laboratories Class A shares in Q3 2020, an estimated $40K.
Bio-Rad Laboratories Class A made up 0.03% of ETrade Capital Management's portfolio in Q3 2020, its #259 holding.
ETrade Capital Management first reported a position in Bio-Rad Laboratories Class A in Q3 2013 and has held it in 8 quarters since.
479 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2020.

Based on ETrade Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.